Single plasma sampling to predict oral clearance of CYP3A probe midazolam1

Acta Pharmacologica Sinica

Volumn 22, Issue 7, 2001, Pages 634-638

  Zhu, B ^a   Ou Yang, D S ^a   Cheng, Z N ^a   Huang, S L ^a   Zhou, H H ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

1 hydroxymidazolam; Cytochrome P 450 CYP3A; Midazolam; Pharmacokinetics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; MIDAZOLAM; MIDAZOLAM MALEATE; NORTRIPTYLINE; ERYTHROMYCIN N DEMETHYLASE; ERYTHROMYCIN N-DEMETHYLASE; N DEMETHYLASE; OXIDOREDUCTASES, N DEMETHYLATING; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; NORMAL HUMAN; PREDICTION; BLOOD; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; HUMAN; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; SUPPORT, NON-U.S. GOV'T;

EID: 0034954107     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. In vitro and in vivo drug interactions involving human CYP3A
2. Noninvasive tests of enzymes
3. Excretion and metabolism of 14C-midazolam in humans following oral dosing
4. Midazolam is metabolized by at least three different cytochrome P450 enzymes
5. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabiolism
6. Difference of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
7. CYP3A activity in African American and European American men: Population differences and functional effect of the CYF3A4 * 1B5′-promoter region polymorphism
8. Determination of midazolam and two of its metabolites in human plasma by high-performance liquid chromatography
9. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A
10. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe
11. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans
12. Phenotyping of drug-metaboilzing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes
13. Use of midazolam as a human cytochrome P450 3A probe; I: In vitro-in vivo correlations in liver transplant patients
14. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
15. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally
16. Use of midazolam as a human cytochrome P450 3A probe; II: Characterization of inter and intra-individual hepatic CYP3A variability after liver transplantation
17. Optimal plasma sampling to predict AUC of the CYP3A probe midazolam (MID)
18. Failure of erythromycin breath test to correlate with midazlam clearance as a probe of cytochrome P4503A